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Abstract 
Background: Multi-drug-resistant Enterococci colonizing the intestinal tract of hospitalized patients are the major 
source of infection as well as nosocomial spread. Despite worldwide increasing rate of multidrug resistant Enterococci 
colonization and infection among hospitalized patients, there is scarcity of data from resource limited setting. The 
present study aimed at determining the antimicrobial resistance profile of Enterococcus species from intestinal tracts 
of hospitalized patients in Jimma, Ethiopia.
Methods: The study was conducted among hospitalized patients at Jimma University Specialized Hospital, from 
January to July 2013. Fecal samples were collected and processed for bacterial isolation and susceptibility testing 
to antimicrobial agents. Stool samples were inoculated onto enterococcus selective media (Bile Esculin azide agar 
plate) with and without 6 µg/ml of vancomycin. The isolates were identified to genus and species level by cultural 
characteristics, Gram’s stain, catalase test, growth in 6.5% NaCl broth, growth at 45°C, motility test and by using API 
20 Streptococcus system. Sensitivity testing was done using Kirby–Bauer disk diffusion method. Minimum inhibitory 
concentrations for vancomycin were determined using E-test strips.
Result: Overall, Enterococci were isolated from 114 (76%) of the study subjects. The isolates were Enterococcus 
faecium (35.1%) followed by Enterococcus faecalis (29.8%), Enterococcus gallinarum (17.5%), Enterococcus casseliflavus 
(8.8%) and Enterococcus durans (8.8%). Among 114 tested Enterococci isolates, 41 (36%) were resistant to ampicillin, 62 
(54.4%) to streptomycin and 39 (34.2%) to gentamycin. Other alternative antibiotics to treat mixed nosocomial infec-
tion caused by Enterococci also showed high rate of resistance in vitro: ciprofloxacin (50% of resistance), norfloxacin 
(49.1%), erythromycin (63.2%), tetracycline (64.9%), chloramphenicol (34.2%), and nitrofrantoin (32.4%). Multiple drug 
resistance was observed among 89.5% of E. faecium and E. faecalis. Vancomycin resistant Enterococci were observed 
in 5% of E. faecium isolates.
Conclusion: This study reveals high rate of fecal colonization by multidrug-resistant Enterococci and prevalence of 
vancomycin resistance strains. Thus periodic surveillance of antibacterial susceptibilities is recommended to detect 
emerging resistance and to prevent the spread of antibacterial-resistant strains.
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Background
Enterococci are Gram-positive cocci that are nor-
mal inhabitants of the gastrointestinal tract. However 
they can also be significant pathogens, causing surgical 
wound infection, bacteraemia, endocarditis, neona-
tal sepsis and rarely meningitis [1]. The most common 
nosocomial infection caused by these organism are 
urinary tract infection (associated with instrumenta-
tion and antimicrobials administration), followed by 
intra-abdominal and pelvic infection [1, 2]. The relative 
importance of Enterococcus as a pathogen has increased 
with the occurrence of high-level resistance to multiple 
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antimicrobial drugs, such as ampicillin, aminoglyco-
sides and vancomycin [3]. The emergence of vanco-
mycin resistance Enterococci (VRE) has alarmed the 
global infectious diseases community due to few option 
left for disease management [4]. Besides drug resistant 
Enterococci colonizing the intestinal tract of hospital-
ized patients are the major source of infection as well as 
nosocomial spread [5]. Several trends have been identi-
fied in the epidemiology of enterococcal infections: an 
increasing incidence of enterococcal infections par-
ticularly among the severely ill hospitalized patients, an 
increasing proportion of nosocomial enterococcal infec-
tions caused by Enterococcus faecium and an increasing 
level of resistance to ampicillin, aminoglycosides, and 
glycopeptides [4–10].
In humans, enterococcal infections may be caused by 
at least 12 species but most clinical infections are due 
to either Enterococcus faecalis or E. faecium [1]. E. fae-
calis is the most common cause (80–90%) followed by 
E. faecium (10–15%). Occasional infections are due to 
Enterococcus gallinarum, Enterococcus raffinosus, Ente-
rococcus casseliflavus, Enterococcus avium, Enterococcus 
pseudoavium, Enterococcus malodoratus, Enterococcus 
mundtii, Enterococcus durans, and Enterococcus hirae [1, 
8]. The proportion of isolates of motile Enterococci (E. 
gallinarum, E. casseliflavus) remained low, i.e. less than 
two per cent. It is important to probably recognize the 
motile Enterococci because they are intrinsically resistant 
to vancomycin (low level) and inappropriate treatment 
with vancomycin may contribute to morbidity and mor-
tality [1, 10].
Several studies have documented that enterococcal 
infections are most commonly caused by the patient’s 
own commensal flora. Colonization may occur long 
before or immediately before infection, but either way, 
it plays a major role in the development of nosocomial 
infection [5]. Despite the importance of these etiologic 
agents there is paucity of information regarding antimi-
crobial resistance of Enterococcus species isolated from 
intestinal tract of hospitalized patients in the country. 
Thus, the present study was conducted to determine anti-
microbial resistance pattern of fecal Enterococci isolates 
collected from hospitalized patients in Jimma, Ethiopia.
Methods
Study design and area
A cross sectional study was conducted at Jimma Univer-
sity Specialized Hospital (JUSH), which is located 354 km 
southwest of Addis Ababa, Ethiopia, from January to July 
2013. JUSH is a referral hospital in Southwestern region 
of the Country.
Study population
One hundred fifty patients, who had at least 10  days 
of hospital stay at Medical and Surgical wards, were 
enrolled.
Specimen collection
A structured questionnaire was used to collect data from 
the patients after obtaining a written informed consent. 
Fecal samples were collected in sterile plastic containers 
which were used for stool collecting and then were trans-
ferred to the laboratory. From critically ill patients rectal 
swabs were collected using sterile cotton swab moistened 
in sterile normal saline solution at intensive care units. 
Then, the swabs were immersed in well-labeled Cary-
Blair semi-solid medium (Oxoid Ltd, Basingstoke, Hamp-
shire, England) prepared in screw-capped tubes.
Culture and identification
Stool specimens and rectal swabs were inoculated onto 
Enterococci selective media [Bile Esculin azide agar 
plates (Oxoid, Dardilly, France)] with and without 6 µg/
ml of vancomycin to recover vancomycin-susceptible iso-
lates and incubated at 37°C for 24 h.
Colonies showing macroscopically morphological dif-
ferences and whose colony morphology was consistent 
with that of Enterococci [colonies with colourless or grey 
and surrounded by a black halo (hydrolysis of esculin)] 
were subcultured and identified as Enterococci by addi-
tional tests (gram stain, catalase test, 6.5% NaCl test, 
growth at 45°C and motility test) as recommended by 
Facklam and Collins [11], Manero and Blanch [12]. Iden-
tification of these isolates to species level was performed 
by API-20 Streptococcus system (bioMe´rieux). For fur-
ther identification, stock cultures were stored at BHI 
Broth containing 50% glycerol at −20°C.
Antibiotic susceptibility testing
Antimicrobial susceptibility studies were performed by 
disc diffusion (Kirby–Bauer) method according to Clini-
cal Laboratory Standards Institute (CLSI) [13]. The drugs 
for disc diffusion testing was obtained from Oxoid in the 
following concentrations: chloramphenicol (CL) (30 μg), 
gentamicin (HLG) (120 μg), norfloxacin (NOR) (30 μg), 
ciprofloxacin (CIP) (5  μg), ampicilin (AMP) (10  μg), 
tetracycline (TE) (30  μg), penicillin (P) (10  IU), eryth-
romycin (ERY) (15  μg), streptomycin (HLS) (300  μg), 
Nitrofrantoin (FD) (300  μg). Minimum inhibitory con-
centrations (MICs) for vancomycin were determined 
using E-test strips (AB Biodisk, Solna, Sweden). E. faeca-
lis ATCC 29212 was used as a quality control strain for 
performing antimicrobial tests.
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Statistical analysis
Data was analyzed using statistical package for social sci-
ence (SPSS) version 16. Statistical evaluations were car-
ried out at 95% CI and p value <0.05 was considered as 
significant.
Ethical considerations
The study was ethically approved by Jimma University 
Ethical Review Board. Written consent was obtained 
from patients after explanation of the purpose of the 
study and procedure of sample collection. Confidential-
ity of any information related with the patient and their 
clinical history was maintained.
Results
Demographic characteristics
Of the 150 patients, 76 (50.7%) were males and 74 
(49.3%) were females resulting in an overall male to 
female ratio of 1:1. The mean age of the patients was 
36 years (range 16–71). Of all 150 study subjects, 92.7% 
had a history of exposure to one or more antimicrobial 
agent in the last 2 weeks and 7.3% were without expo-
sure and the average hospital stay was 19.5 days with a 
range of 10–60.
Enterococci isolates
Overall, Enterococci were isolated from 114 (76%) of 
the study subjects, There was no statistically signifi-
cant difference in the isolation of Enterococci with age 
(P = 0.432), sex (P = 0.546), hospital duration (0.135) and 
antibiotic history (P = 0.313) as is shown in Table 1.
Species distribution
The distribution of species is shown in Figure 1. A total 
of 114 enterococcal isolates were obtained from 150 
patients. The commonly enterococcal isolates were 
E. faecium (35.1%) followed by E. faecalis (29.8%), E. gal-
linarum (17.5%), E. casseliflavus (8.8%) and E. durans 
(8.8%).
Antimicrobial resistance of Enterococcal isolates
Antimicrobial resistance of isolated Enterococci are sum-
marized in Table 2.
β‑Lactam resistance
Five of thirty-four (14.71%) E. faecalis and 35/40 (87.5%) 
E. faecium were resistant (overall 41/114; 35.96%) to 
ampicillin. Notably all E. faecalis and E. faecium isolates 
were resistant to penicillin. Eleven of fourty (27.5%) occa-
sional Enterococcus species (E. gallinarum, E. durans 
and E. casseliflavus) were resistant to penicillin.
Aminoglycoside resistance
High-level resistance to gentamicin and streptomy-
cin was detected by the high content disk. Gentamycin 
resistant were observed in 26.5% of E. faecalis and 75% of 
E. faecium. Eighteen of thirty-four (52.9%) E. faecalis and 
62.5% E. faecium were resistant to streptomycin.
Vancomycin‑resistant Enterococci
None of the E. faecalis isolates tested exhibited resistance 
to vancomycin while 2 (5%) of E. faecium isolates were 
resistant to vancomycin.
Table 1 Comparison of demographic characteristics 
and Enterococcus culture positivity among hospitalized 






Age category in years
 16–27 42 (76.4%) 13 (23.6%) 55 (36.7%) 0.432
 28–55 62 (73.8%) 22 (26.2%) 84 (56%)
 56 and 
above
10 (90.9%) 1 (9.1%) 11 (7.3%)
Sex
 Male 57 (74%) 20 (26%) 77 (51.3%) 0.546
 Female 57 (78.1%) 16 (21.9%) 73 (48.7%)
Hospital duration
 10–30 days 92 (73.6%) 33 (26.4%) 125 (83.3%) 0.135
 31 and 
above
22 (88%) 3 (12%) 25 (16.7%)
Previous antibiotic treatment
 Yes 103 (74.1%) 36 (25.9%) 139 (92.7%) 0.313
 No 10 (90.9%) 1 (9.1%) 11 (7.3%)
Figure 1 Distribution of Enterococcus species isolated from intesti-
nal tract of hospitalized patients in Jimma, Ethiopia.
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Other antimicrobials
Alternative antibiotics to treat infection by Entero-
coccus also showed high rate of resistance. Resistance 
to ciprofloxacin was observed in 50% of the isolates, 
49.1% to norfloxacin, 63.2% to erythromycin, 34.2% to 
chloramphenicol, 64.9% to tetracycline and 32.4% to 
nitrofrantoin.
The drug resistance among the isolates is shown in 
Table 3. Out of 114 Enterococci isolates 102 (89.5%) were 
resistant to three antibiotics, 55 (48.2%) were resistant 
to four antibiotics and 29 (25.4%) were resistant to three 
antibiotics from different antibiotics classes.
The combined high level aminoglycoside and ampicil-
lin resistance among the Enterococci isolates is shown in 
Table 4. Resistance among E. faecium isolates was higher 
than E. faecalis (85.7 vs. 14.7%).
Discussions
The rapid emergence of resistance in Enterococci and the 
increasing incidence of colonization and infection with 
VRE have become health care issues that have caused 
serious concern to physicians and health authorities alike 
[4]. This study investigated the prevalence of Enterococci 
and antibacterial resistance patterns of Enterococci iso-
lated from fecal samples of hospitalized patients in wards 
that have high-risk for VRE colonization in JUSH.
The increase of invasive infections caused by multi-
resistant E. faecium, however, did not only increase the 
total burden of nosocomial enterococcal infections, but 
Table 2 Antibiotic resistance profile of Enterococcus species by Kirby–Bauer disc diffusion method from intestinal tract of 
hospitalized patients in Jimma, Ethiopia
HLR-GN high level resistance to gentamycin, HLR-ST high level resistance to streptomycin.
a Other species consists of E. gallinarum (n, 20), E. durans (n, 10) and E. casseliflavus (n, 10).
Antibiotics Resistant isolates (%)
E. faecalis (n, 34) E. faecium (n, 40) Other speciesa (n, 40) Total (n, 114)
Ampicillin 5 (14.7) 35 (87.5) 1 (2.5) 41 (36)
Penicillin 34 (100) 40 (100) 11 (27.5) 85 (74.6)
Gentamicin (HLR-GN) 9 (26.5) 30 (75) 1 (2.5) 40 (35.1)
Streptomycin (HLR-ST) 25 (73.5) 36 (90) 1 (2.5) 62 (54.4)
Ciprofloxacin 21 (61.8) 35 (87.5) 1 (2.5) 57 (50)
Norfloxacin 20 (58.8) 34 (85) 2 (5) 56 (49.1)
Erythromycin 25 (73.5) 39 (97.5) 8 (20) 72 (63.2)
Chloramphenicol 25 (73.5) 11 (27.5) 3 (7.5) 39 (34.2)
Tetracycline 32 (94.1) 37 (92.5) 5 (12.5) 74 (64.9)
Nitrofrantoin 17 (50) 18 (45) 2 (5) 37 (32.4)
Table 3 Multidrug-resistance patterns of E. faecium and E. faecalis from intestinal tract of hospitalized patients in Jimma, 
Ethiopia
MDR non-susceptible to ≥1 agent in ≥3 antimicrobial categories, R3 resistance to three antibiotics, R4 resistance to four antibiotics, R5 resistance to five antibiotics, R6 
resistance to six antibiotics, R7 resistance to seven antibiotics, AMP ampicilin, HLR-GN high level resistance to gentamycin, TE tetracycline, FD Nitrofrantoin, CIP cipro-
floxacin, CL chloramphenicol, ERY erythromycin, VA vancomycin.
No. of antibiotics Resistance patterns Number of E. faecium  
with pattern
Number of E. faecalis  
with pattern
Total number  
of MDR (%)
R3 AMP, HLR-GN, TE 30 5 102 (89.5)
HLR-GN, TE, FD 16 5
TE, FD, CIP 17 13
FD, ERY, CL 5 11
R4 AMP, HLR-GN, TE, FD 16 3 55 (48.2)
HLR-GN, TE, FD, CIP 16 4
TE, FD, ERY, CL 5 11
R5 AMP, HLR-GN, TE, FD, CIP 16 2 29 (25.4)
HLR-GN, TE, FD, ERY, CL 5 4
TE, FD, ERY, CL, VA 2 0
R6 HLR-GN, TE, FD, ERY, CL, VA 2 (100) 0 2 (1.75)
R7 AMP, HLR-GN, TE, FD, ERY, CL, VA 2 (100) 0 2 (1.75)
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also resulted in a partial replacement of E. faecalis by 
E.  faecium as a cause of hospital-associated infections 
[4]. Several studies showed that an increased proportion 
of nosocomial enterococcal infections caused by E. fae-
cium [14–17]. The isolates obtained in this study were 
E. faecium (35.1%) followed by E. faecalis (29.5%) while 
E. gallinarium, E. casseliflavus, and E. durans accounted 
for 17.5, 8.8 and 8.8% of the isolates, respectively. This 
species distribution is comparable to the distribution of 
enterococcal species in other studies [18, 19]. But it is 
in disagreement with reports from United States where 
E. faecalis was predominant over E. fecium isolates from 
intestinal tract of hospitalized patients [20].
In our study, the predominant enterococcal isolates 
was E. faecium, which is in concurrence with a recent 
report from India that described 81% of blood isolates as 
E. faecium [21]. Study in Singapore has also reported an 
increase in E. faecium from 78.9 to 91.8% over a period 
of 5  years from 2006 to 2010 from clinical cultures 
[22]. Another study from India has also reported 66% 
of blood isolates as E. faecium [17]. Iwen et  al. [14] has 
also reported an increase in E. fecium isolates from 12.9 
to 36.3 over a period of 8 years during 1987–1995 from 
blood cultures.
Although motile Enterococci, including E. galli-
narum and E. casseliflavus, are infrequently isolated 
from clinical specimens, they have been implicated in a 
wide variety of invasive infections in humans, especially 
immunocompromised or chronically ill patients, and 
sometimes are nosocomially acquired [23, 24]. In our 
study the prevalence of 17.5% of E. gallinarum, 8.8% of 
E. casseliflavus and 8.8% of E. durans was significantly 
higher than in several studies conducted elsewhere 
[18, 25, 26], although we don’t have explanation for this 
finding.
The enterococcal isolates possess an intrinsically rela-
tive resistance to penicillin and ampicillin. Further-
more, E. faecium is less susceptible to β-lactam agents 
than E. faecalis because their penicillin-binding proteins 
(PBPs) have lower affinities for these antibiotics and 
some strains have plasmid-encoded β-lactamase [1]. In 
our study, the 14.7% resistance rate to ampicillin in E. 
faecalis isolates was higher than the 0–8.3% resistance 
rates reported in Kuwait, Hong Kong, and Brazil [5, 
18, 27] and comparable to 15% resistant rates reported 
in Iran [28] and 15.7% in Saudi Arabia [25] and lower 
than 60.7% reported in Gaza [29] and 66% in India [30]. 
Resistance rates to ampicillin was observed in 87.5% of 
E. faecium isolates which is higher than 31.4% resistance 
rates reported from Hong Kong [5] and 66.7% in Gaza 
[29]. However, similar to 87.5% resistance rate reported 
from Israel among high risk patients [31] and compara-
ble to 82% resistant rate reported from Iran [32]. All E. 
faecalis and E. faecium isolates were resistant to penicil-
lin which is similar rate of resistance reported from India 
in clinical isolates [17]. The reason for higher prevalence 
of β-lactam antibiotic resistance in the examined wards 
(JUSH) might be because of the set up where chronic 
cases are prevalent and there is a wider usage of broad 
spectrum antibiotics relative to other wards.
Aminoglycosides are frequently used in combina-
tion with cell-wall-active antibiotics for severe entero-
coccal infections [4]. Since enterococcal resistance to 
gentamicin and streptomycin occurs by different mecha-
nisms, it is important to test susceptibility to both agents. 
Enterococci with high level resistance to streptomycin 
are susceptible to gentamicin. Gentamicin resistance is 
a good predictor of resistance to other aminoglycosides 
except streptomycin [1].
Although high-level aminoglycoside resistance 
(HLAR) may be regarded as important for severe infec-
tions, we determined the high-level resistance in vari-
ous species to get an idea of the frequency of this kind 
of resistance in the enterococcal isolates of fecal samples 
in hospitalized patients. In the present study high-level 
resistance to gentamicin or streptomycin were observed 
in 34.2 and 54.4% of Enterococci isolates, respectively. 
These results are comparable to resistance rate reported 
from Hong Kong and Japan [5, 33] and higher than 
resistance rate reported from Kuwait and Saudi Arabia 
[18, 25]. When high-level resistance to gentamicin and 
streptomycin occurs in the same strain, it means that, 
with few exceptions, there is no reliable bactericidal 
regimen [1]. In our study, E. faecalis and E. faecium 
showed resistance to as many as nine drugs. Concomi-
tant resistance of high level aminoglycoside resistance 
(HLAR) strains to the β-lactam antibiotic (ampicil-
lin) was quite higher (14.7% of E. faecalis and 85.7% of 
E. faecium strains) (Table  4). This finding is a cause of 
concern, because the synergistic activity of the combi-
nation of β-lactam antibiotics with HLAR in the treat-
ment of enterococcal infections is totally abolished. In 
Table 4 Combined high level aminoglycoside and ampi-
cillin resistance of E. faecium and E. faecalis isolates from 
intestinal tract of hospitalized patients in Jimma, Ethiopia








AMP AMP, HLR-GN, 
HLR-ST
E. faecium (40) 30 (75) 35 (87.5) 30 (75)
E. faecalis (34) 8 (23.5) 5 (14.7) 5 (14.7)
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such instances, controlling the spread of these organisms 
becomes of paramount importance.
Because of high prevalence of concomitant resistance, 
attempts had been made to look for alternative antibiotics 
in different studies. Fluroquinolones have been among the 
dominant class of antimicrobial agents in the last decade 
and are widely used for nosocomial infections empirically 
[34]. In our study 50% of Enterococci isolate were resist-
ant to ciprofloxacin and 49.1% of the isolates were resist-
ant to norfloxacin. Other alternative antibiotics to treat 
infection by Enterococcus also showed high rates of resist-
ance in vitro: erythromycin (63.2% of resistance), tetracy-
cline (64.9%), chloramphenicol (34.2%), and nitrofrantoin 
(32.4%). This widely used class of antimicrobial agent for 
empirical treatment of mixed nosocomial infections caused 
by Enterococci could not be effective in our setting because 
of high rates of resistance according to the present study.
The emergence of VRE is also due to the inappropriate use 
of cephalosporin as well as poor hospital infection control 
measures [1, 35]. As our results showed 2 out of 40 E. fae-
cium strains (5%) were vancomycin resistant which is com-
parable with 4% VRE strains report from Egypt [36] and 6.2% 
from Iran [37]. Lower than 10.2% report from South Africa 
[38], 12% report from Korea [39] and 34.8% report from Tur-
key [40]. The possible reason for the emergence of VRE in 
studied hospital (JUSH) may possibly be antibiotic selective 
pressure because the patients in the studied units (medical 
and surgical ward) had long duration of hospital stay and 
high rate of antibiotics treatment relative to the other wards 
which are the most frequently reported risk factor for multi-
resistance Enterococci colonization and infection.
Conclusions
The prevalence of VRE in faeces of hospitalized patients 
at JUSH was 5%. High percentage of multi-drug resist-
ance was also observed in the majority of the isolates. 
Overall, multiple drug resistance was observed among 
89.5% of E. faecium and E. faecalis. The emergence of 
VRE (5%) and the high rate of fecal colonization by 
multi-resistant Enterococci in this study call for peri-
odic surveillance of antibacterial susceptibilities to detect 
emerging resistance and prevent the spread of antibacte-
rial-resistant strains.
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